Auauniversity

At the conclusion of this activity, participants will be able to: 1. Describe new and emerging targeted for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy. 2. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC. 3. Facilitate discussions with patients and caregivers regarding RCC treatment options. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29851

Immune Checkpoint Inhibitors in RCC At the conclusion of this activity, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage immune related adverse events. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29846

The Expanding Role of Immune Checkpoint Inhibitors in MIBC and NMIBC At the conclusion of this activity, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29831

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 At the conclusion of this activity, participants will be able to: 1. Analyze breakthrough treatments in the management of advanced and metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC). 2. Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC. 3. Describe the indications, sequencing and combinations for treatment with approved agents in the management of mHSPC and nmCRPC. This educational series is supported by independent educational grants from: Astellas AstraZeneca Bristol Myers Squibb Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc Sanofi Genzyme UroGen Pharma, Inc. CME Available: https://auau.auanet.org/node/29816

Course Description: The course is centered on reviewing medical management and prevention of kidney stones. A focus is on the AUA guidelines for the medical management of stones. The course is focused on practical information, for example, how to interpret 24 hour urines, when to prescribe medication. It also has a focus on dietary management for stones. Learning Objectives: Upon completion of this activity, participants will be able to: 1. Interpret a 24 hour urine collection and identify underlying metabolic causes for recurrent stone disease. 2. Prescribe appropriate medical treatment for the prevention of kidney stones based on findings on a 24 hour urine collection. 3. Prescribe targeted dietary changes for underlying metabolic abnormalities on 24 hour urine testing such as hypercalciuria, hyperoxaluria, and hypocitraturia.

Course Description: The diagnosis and management of Male Lower Urinary Tract Symptoms (mLUTS) and benign prostatic hyperplasia (BPH) has evolved dramatically over the past 5 years with changing algorithms. The AUA BPH Guidelines were revised in 2018 focusing primarily on diagnostic algorithms and surgical modalities. The 2020 Guidelines will incorporate recommendations about medical therapies. This course is designed to review, discuss and develop a coherent diagnostic and treatment strategy for men with mLUTS. This will include risk factors such as obesity, the role of both AUA and international guidelines, established algorithms, medical therapy with both mono and combination therapy with agents such as alpha blockers, antimuscarinics, beta - 3 agonists, 5-alpha reductase inhibitors, PDE - 5 inhibitors and surgical options including minimally invasive (UroLift / Rezum) and surgical options (electrosurgical, laser, aquablation). In addition, how these agents dovetail with sexual function and testosterone rep

This educational series is supported by an independent educational grant from: AstraZeneca; Merck; Pfizer Inc. CME Available: https://auau.auanet.org/node/29200 Course Description: Over the last several years, there has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer. Urologists are suddenly being confronted with new information surrounding screening guidelines for men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations. To increase urologists understanding related to the newest treatment options for prostate cancer, the featured 60-minute panel discussion led by experts in their field, will explore how to translate the latest scientific advances into routine clinical practice, improving the care of patients who are at a markedly-elevated risk of progressions and death from prostate can

Join Drs. Brian Matlaga and Ryan Hsi as they share insights into diagnostics, therapeutic options, and treatment outcomes for urinary stone disease. Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guest: Ryan Hsi, MD, Vanderbilt University This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.

Course Description: This course tackles key controversies in surgical stone disease and elucidates the most current rationale to varying treatments using a case-based scenarios. Two well-known senior experts give honest and clear assessments of the field in these controversial areas. Active discussion is encouraged, and the discussion favors more experienced endourologists. Controversies include: dusting vs basketing, mini PCNL vs. standard PCNL, supine vs prone PCNL, micro PCNL vs ureteroscopy, wireless vs safety wire ureteroscopy, stents vs no stents, SWL vs URS and retrograde vs. antegrade caliceal diverticular stone treatments. Learning Objectives Upon completion of this activity, participants will be able to: 1. Apply standard therapy to complex problems. 2. Counsel patients and colleagues regarding controversial topics in stone management. 3. Manage all aspects of a complex surgical stone case.

This course will assist Urologists and Allied staff in understanding the evidence-base and the clinical role of the newly-introduced techniques for treating BPH and LUTs. The technology behind each will be reviewed and the quality of the data supporting each will be examined with emphasis placed on the Pivotal trials and their methodology. The current Guidelines will be reviewed and a practical discussion of the peri-operative considerations and tips and tricks for the use of each will be covered. Upon completion of this activity, participants will be able to: 1. Differentiate between each of the new technologies for treating BPH/LUTS both based on mode-of-action and the quality of supporting evidence. 2. Describe the features expected of a Pivotal Trial for BPH Medical Devices and be able to compare and contrast the findings of these trials for each of the current devices. 3. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectati

This course will review the new AUA guidelines on premature ejaculation and delayed ejaculation. The course will provide a clinical framework for the diagnosis, evaluation, treatment and follow-up of patients with ejaculation disorders based on the best available published literature. The course will review correct application of the new AUA guidelines in clinical practice. This course will be a benefit to practicing urologists, primary care providers, other non-physician providers, residents preparing for their certification exam and physicians preparing for their re-certification exam. Upon completion of this activity, participants will be able to: 1. Analyze the latest evidence on the management of disorders of ejaculation as outlined in the AUA guidelines. 2. Recognize the role of mental health professionals in managing disorders of ejaculation. 3. Improve the diagnostic and therapeutic decision making processes by understanding the evidence basis of these guidelines in urological practice. 4. Acquire

This course will address the timely and accurate diagnosis of testicular cancer and emphasize the appropriate integration of pathologic, radiographic and serologic variables in assessing individual patient's risk in both low and high-stage germ cell tumors (GCT). Important features regarding the natural history of GCTs will also be emphasized. Patient selection and treatment options for patients with clinical stage I non-seminomatous germ cell tumors (NSGCT) such as surveillance, 1° retroperitoneal lymph node dissection (RPLND) and chemotherapy will be discussed. Upon completion of this activity, course participants will be able to: 1. Cite current concepts and controversies in the management of low-stage and high-stage nonseminomatous germ cell tumors (NSGCTs). 2. Discuss current concepts and controversies in the management of low-stage and high-stage seminoma. 3. Describe the biology and clinical implications of teratoma. 4. Illustrate importance of tumor markers and their role in diagnosis, follow up and

This interactive webinar will answer questions medical students have regarding facilitation of remote exposure to urology training programs, and the resources available to support urologic education for medical students. Our panel consists of members of the Society of Academic Urologists who will share their insights to help you navigate remote urologic training

This course will focus on what general urologists who have not had fellowship or specialty training in male infertility can do to evaluate and treat male reproductive disorders. Basic science presented will be limited to that which is absolutely essential to understand the basic evaluation and treatment. In 90% of male infertility cases, a good history and careful physical examination, along with a basic semen analysis, which can often be performed by the doctor himself, will allow the general urologist to come up with a tentative diagnosis and treatment plan. More advanced testing is primarily designed to confirm the diagnosis. Key points of history, including inheritance issues, will be discussed. The finer points of physical examination, which in male infertility, due to the ready accessibility of the male reproductive organs to physical examination of a relaxed scrotum, allows the diagnosis to be made without the necessity for imaging studies in the majority of men. Interpretation of semen analysis will b

This course will teach the urologist and advanced practice provider the skills needed to better communicate with the female patient about her sexual health needs and better manage her sexual dysfunctions. The course will start with normal physiology and pathophysiology of the genitals including how to examine them under magnification in order to better understand sexual dysfunctions in women. Diagnostic tools and treatment strategies for the management of desire, arousal, orgasm and pain disorders including unusual arousal/orgasm issues such as persistent genital arousal disorder will be discussed. Included in this course is an overview of to use the latest FDA approved drugs, off label options, devices such as CO2 fractional laser and surgical therapies. Women with distressing sexual health concerns should undergo biopsychosocial diagnostic evaluations to assess pathophysiology, starting with a history and physical with vulvoscopy. Risks and benefits of hormone therapy for pre- and post-menopausal women will

Our ability to diagnose, treat, and manage rUTI has evolved due to additional insights into the pathophysiology of rUTI, a new appreciation for the adverse effects of antimicrobial therapy, rising rates of bacterial antimicrobial resistance, and improved reporting of the natural history and clinical outcomes of acute cystitis and rUTI. This course will review the new AUA guideline on recurrent UTIs in the index female patient. The guidelines encompass rUTI diagnosis, treatment, antibiotic and other methods of prophylaxis. The evidence supporting the guidelines will be presented in a case-based fashion. A treatment algorithm which includes the most current and safe antibiotic regimens will be provided. Faculty are all members of the AUA 2019 guideline panel and include urologists and an internist with expertise in Infectious Diseases. Upon completion of this activity, participants will be able to: 1. Demonstrate knowledge of the evidence and rationale behind the 2019 recurrent UTI guidelines. 2. Formulate a

Join Drs. Kevin McVary and Charles Welliver with host Dr. Brian Matlaga as they present BPH findings from the Urologic Diseases in America Report. Host: Brian Matlaga, MD, MPH, Johns Hopkins University School of Medicine Guests: Kevin McVary, MD, Loyola University Medical Center and Charles Welliver, MD, Albany Medical College This project has been funded in whole or in part with Federal funds from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N94019F00260.

This course on IC/BPS is designed for the urologist, gynecologist, and advanced practice providers who see these patients and are responsible for their medical care. It is designed to focus on what we know, what we have learned from recent research efforts, how we can best use our knowledge in the care of these patients, and what may be coming in the future. We will discuss definition, nomenclature, epidemiology, possible etiology, and review the latest American Urological Association guideline which provides a working framework from which to practice. The issue of phenotyping, an important new focus on clinical trials, will be highlighted. We will review the major findings of the NIDDK Multidisciplinary Approach to the study of Pelvic Pain (MAPP) which is completing a decade of intensive research on this syndrome. How might this research inform and translate into the clinical arena and help our patients. Upon completion of the activity, participants will be able to: 1. Recall the AUA guidelines and descri

To utilize a case-based and interactive approach to highlight key components of the current AUA Guidelines for the Medical and Surgical Management of Kidney Stones. The course will additionally provide updated literature and topics in the management of stone disease which may impact future Guideline statements. During this course, representative basic and complex clinical cases/vignettes will be discussed with the use of data from the comprehensive guidelines to demonstrate critical points. Use of the audience response system and Q/A between cases amongst the faculty and audience members will be critical to the success of the course. Important aspects regarding metabolic evaluation, medical management, preoperative evaluation, imaging techniques, and surgical treatment recommendations (as well as surgical approaches and complications) in adult, pediatric, pregnant, and complex patients will be illustrated. The faculty will also reference the Guideline Statements that provide the framework for their decision-m

Host: Victor Nitti, MD Guest: David Shin, MD Chronic orchialgia or testicular pain is a challenging disease to treat for both the patient and urologist because the perception and resolution of pain is often subjective in nature. With a national trend towards treatment away from opioid use, it is important that clinicians utilize an algorithm focusing on non-narcotic use for medication treatment as well as be able to offer office-based or surgical therapies when medical therapy fails. After today’s podcast, learners will be able to: 1. Compare and contrast pathological and non-pathological etiologies of scrotal pain 2. Summarize the rationale for different medication therapies and incorporate an algorithm for treatment 3. Distinguish various surgical treatment options depending upon etiology